Mobile Site ›
Print Page Email Page

Interpretive Handbook

‹ Back to index | Back to list | More information

Test 80309:
Apolipoprotein A1, Plasma

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Apolipoprotein AI (Apo AI) is 1 of the apoproteins of high-density lipoproteins (HDL). Plasma HDL cholesterol concentration is inversely related to the risk for coronary artery disease. Individuals with Tangier disease have <1% the normal amount of HDL and thus Apo AI.

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluation of risk for atherosclerotic disease

 

Detection of Tangier disease

Interpretation Provides information to assist in interpretation of the test results

Values less than approximately 90 mg/dL indicate increased risk for atherosclerotic disease.

 

Blood plasma of persons with Tangier disease contains no more than 1% of the Apolipoprotein AI present in normal plasma.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Fasting for <12 hours or intake of alcohol during the 24 hours prior to specimen collection may invalidate test results.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

> or =18 years: 106-220 mg/dL

Reference values have not been established for patients that are less than 18 years of age.

Clinical References Provides recommendations for further in-depth reading of a clinical nature

1. Franzen J, Fex G: Low serum apolipoprotein A-1 in acute myocardial infarction survivors with normal HDL cholesterol. Atherosclerosis 1986;59:37-42

2. Sniderman A, Shapiro S, Marpole D, et al: Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low density [beta] lipoproteins]. Proceedings of the National Academy of Science USA 1980;77:604-608